Volume 29, Number 8—August 2023
Research
Economic Evaluation of Wastewater Surveillance Combined with Clinical COVID-19 Screening Tests, Japan
Table 2
Table 2. Base-case analysis with a deterministic model in an economic evaluation of wastewater surveillance combined with clinical COVID-19 screening tests, Japan* |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Incidence† | Option 1 |
Option 2 |
Relative value of option 2 |
||||||||
Cost | Benefit | ROI‡ | Cost | Benefit | ROI‡ | Incremental cost§ | Incremental benefit¶ | Relative ROI# | |||
10 | $67.04 | $1.39 | 0.021 | $53.60 | $1.14 | 0.021 | –$13.44 | –$0.25 | 54 | ||
100 | $67.05 | $14.09 | 0.21 | $53.61 | $11.94 | 0.22 | –$13.43 | –$2.15 | 6.25 | ||
1,000 | $67.12 | $141.11 | 2.10 | $53.75 | $119.94 | 2.23 | –$13.37 | –$21.16 | 0.63 |
*Option 1 is clinical testing only; option 2 is wastewater surveillance and clinical testing. If one option is cost-saving compared with its comparator, the option’s ROI is estimated to exceed 1. The comparator of options 1 and 2 is do-nothing. All monetary values are expressed in 2022 US dollars (USD). ROI, return on investment. †Disease incidence per day per 1 million residents in the area. ‡ROI is benefit divided by cost for each option. §Incremental cost is the cost of option 2 minus cost of option 1. A negative value of incremental cost indicates that option 2 has a lower cost or is cost-saving, compared with option 1. This could be interpreted as option 2’s relative benefit. ¶Incremental benefit is the benefit of option 2 minus benefit of option 1. A negative value of incremental benefit indicates that option 2 has a lower benefit compared with option 1, which could be interpreted as option 2’s relative cost. #Relative ROI is incremental cost divided by incremental benefit.